Author

Chen-Yang Ye

Institution: Shanghai Changzheng Hospital

Observed institutions: Second Military Medical University, Shanghai Changzheng Hospital

ORCID: 0000-0002-9364-693X

Observed ORCID: 0000-0002-9364-693X

OpenAlex ID: A5045709286

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report

2022 · Zhan Wang, Yan Geng, et al. · Frontiers in Oncology · 31

Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer

2022 · Zhan Wang, Miao-Miao Wang, et al. · Journal of Translational Medicine · 25

Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial

2022 · Zhan Wang, Bao-Dong Qin, et al. · European Journal of Cancer · 21

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial

2025 · Zhan Wang, Bao-Dong Qin, et al. · Signal Transduction and Targeted Therapy · 7

The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report

2020 · Zhan Wang, Chen-Yang Ye, et al. · OncoTargets and Therapy · 5

Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial

2025 · Ke Liu, Bao-Dong Qin, et al. · Nature Communications · 3

Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAF V600E -mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled trial.

2025 · Zhan Wang, Chen-Yang Ye, et al. · Journal of Clinical Oncology

Works count: 7

Citation count: 92

H-index: 5

I10-index: 3